학술논문
Cost of illness of metastatic prostate cancer: a perspective of costs for new treatment options in The Netherlands
Document Type
Article
Author
Source
Journal of Comparative Effectiveness Research; October 2017, Vol. 6 Issue: 7 p575-581, 7p
Subject
Language
ISSN
20426305; 20426313
Abstract
Aim:To assess the resource use and associated costs of treating patients with metastatic prostate cancer with a focus on skeletal-related events (SREs). Methods:We performed a bottom-up cost of illness study in The Netherlands. Results:A total of 136 patients were studied. The mean total costs were €17,931 per patient. SREs that required hospitalization (n 53) were, at median costs of €2039–9346, depending on care. These SREs had median costs of €200–1912. Conclusion:Our data provide a basis to investigate the cost–effectiveness of novel treatment options for metastatic prostate cancer. The impact of SREs on total costs could justify policy aimed at actively preventing SREs, possibly resulting in better quality of life and cost-reduction.